-
市场
-
产品
-
资讯
-
Moo社区
-
课堂
-
查看更多
-
功能介绍
-
费用费用透明，无最低余额限制
投资选择、功能介绍、费用相关信息由Moomoo Financial Inc.提供
- English
- 中文繁體
- 中文简体
- 深色
- 浅色
Pyxis Oncology (NASDAQ:PYXS) Given Outperform Rating at Lifesci Capital
Pyxis Oncology (NASDAQ:PYXS) Given Outperform Rating at Lifesci Capital
Lifesci Capital restated their outperform rating on shares of Pyxis Oncology (NASDAQ:PYXS – Get Rating) in a research note released on Thursday morning, PriceTargets.com reports.
Pyxis Oncology Stock Down 4.5 %
Shares of PYXS stock opened at $1.39 on Thursday. The business's fifty day simple moving average is $1.65 and its 200-day simple moving average is $2.25. Pyxis Oncology has a 12-month low of $1.34 and a 12-month high of $12.38.
Get Pyxis Oncology alerts:Pyxis Oncology (NASDAQ:PYXS – Get Rating) last issued its quarterly earnings results on Tuesday, November 1st. The company reported ($0.85) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.76) by ($0.09). As a group, research analysts forecast that Pyxis Oncology will post -3.64 earnings per share for the current year.
Hedge Funds Weigh In On Pyxis Oncology
A number of large investors have recently made changes to their positions in the business. Tang Capital Management LLC increased its position in shares of Pyxis Oncology by 2.4% during the third quarter. Tang Capital Management LLC now owns 1,411,569 shares of the company's stock worth $2,781,000 after purchasing an additional 32,489 shares in the last quarter. Vanguard Group Inc. increased its position in shares of Pyxis Oncology by 8.0% in the 3rd quarter. Vanguard Group Inc. now owns 917,384 shares of the company's stock valued at $1,807,000 after acquiring an additional 68,304 shares during the period. Citadel Advisors LLC increased its position in shares of Pyxis Oncology by 0.6% in the 3rd quarter. Citadel Advisors LLC now owns 1,530,785 shares of the company's stock valued at $3,015,000 after acquiring an additional 9,849 shares during the period. Renaissance Technologies LLC increased its position in shares of Pyxis Oncology by 70.9% in the 3rd quarter. Renaissance Technologies LLC now owns 128,802 shares of the company's stock valued at $254,000 after acquiring an additional 53,431 shares during the period. Finally, Tower Research Capital LLC TRC increased its position in shares of Pyxis Oncology by 414.2% in the 3rd quarter. Tower Research Capital LLC TRC now owns 15,736 shares of the company's stock valued at $31,000 after acquiring an additional 12,676 shares during the period. 71.59% of the stock is owned by institutional investors and hedge funds.Pyxis Oncology Company Profile
(Get Rating)
Pyxis Oncology, Inc, a preclinical stage biopharmaceutical company, engages in the development of therapies to treat cancers. Its immune-oncology product candidates include PYX-106, an investigational fully human immunoglobulin G1 isotype siglec-15 targeting antibody for the treatment of thyroid cancer, head and neck squamous cell carcinoma, non-small cell lung cancer (NSCLC), and other solid tumors; and PYX-102, an investigational immune-therapeutic for treatment of solid tumors.
Read More
- Get a free copy of the StockNews.com research report on Pyxis Oncology (PYXS)
- Why CSL Ltd Stock Could Be Worth a Look
- MarketBeat: Week in Review 11/28 – 12/02
- Okta Inc Celebrates Earnings Beat But Can They Sustain the Boost?
- Institutions Are Buying Ambarella, Should You?
- Can ZIM Defy Broad Downturn In The Container Shipping Industry?
Receive News & Ratings for Pyxis Oncology Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pyxis Oncology and related companies with MarketBeat.com's FREE daily email newsletter.
Lifesci Capital restated their outperform rating on shares of Pyxis Oncology (NASDAQ:PYXS – Get Rating) in a research note released on Thursday morning, PriceTargets.com reports.
Lifesci Capital重申了对以下股票的跑赢大盘评级 Pyxis Oncology（纳斯达克股票代码：PYXS — 获取评级） PriceTargets.com在周四上午发布的一份研究报告中报道。
Pyxis Oncology Stock Down 4.5 %
Pyxis Oncology 股票下跌 4.5%
Shares of PYXS stock opened at $1.39 on Thursday. The business's fifty day simple moving average is $1.65 and its 200-day simple moving average is $2.25. Pyxis Oncology has a 12-month low of $1.34 and a 12-month high of $12.38.
周四，PYXS股票开盘价为1.39美元。该公司的五十天简单移动平均线为1.65美元，其200天简单移动平均线为2.25美元。Pyxis Oncology创下12个月低点1.34美元，12个月高点为12.38美元。
Pyxis Oncology (NASDAQ:PYXS – Get Rating) last issued its quarterly earnings results on Tuesday, November 1st. The company reported ($0.85) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.76) by ($0.09). As a group, research analysts forecast that Pyxis Oncology will post -3.64 earnings per share for the current year.
Pyxis Oncology（纳斯达克股票代码：PYXS — Get Rating）最后一次发布季度财报是在11月1日星期二。该公司公布了本季度每股收益（0.85 美元），比分析师普遍预期的（0.76 美元）低于（0.09 美元）。总体而言，研究分析师预测，Pyxis Oncology本年度的每股收益将为-3.64。
Hedge Funds Weigh In On Pyxis Oncology
对冲基金对 Pyxis Oncology 进行了权衡
Pyxis Oncology Company Profile
Pyxis 肿瘤学公司简介
(Get Rating)
（获取评分）
Pyxis Oncology, Inc, a preclinical stage biopharmaceutical company, engages in the development of therapies to treat cancers. Its immune-oncology product candidates include PYX-106, an investigational fully human immunoglobulin G1 isotype siglec-15 targeting antibody for the treatment of thyroid cancer, head and neck squamous cell carcinoma, non-small cell lung cancer (NSCLC), and other solid tumors; and PYX-102, an investigational immune-therapeutic for treatment of solid tumors.
Pyxis Oncology, Inc是一家临床前阶段的生物制药公司，从事癌症治疗疗法的开发。其免疫肿瘤学候选产品包括 PYX-106，一种用于治疗甲状腺癌、头颈部鳞状细胞癌、非小细胞肺癌 (NSCLC) 和其他实体瘤的在研全人免疫球蛋白 G1 同型 siglec-15 靶向抗体；以及 PYX-102，一种用于治疗实体瘤的在研免疫疗法。
Read More
阅读更多
- Get a free copy of the StockNews.com research report on Pyxis Oncology (PYXS)
- Why CSL Ltd Stock Could Be Worth a Look
- MarketBeat: Week in Review 11/28 – 12/02
- Okta Inc Celebrates Earnings Beat But Can They Sustain the Boost?
- Institutions Are Buying Ambarella, Should You?
- Can ZIM Defy Broad Downturn In The Container Shipping Industry?
- 免费获取 StockNews.com 关于 Pyxis Oncology (PYXS) 的研究报告
- 为什么 CSL Ltd 的股票值得一看
- MarketBeat：本周回顾 11/28 — 12/02
- Okta Inc庆祝盈利突破但他们能否维持增长？
- 机构正在收购安巴雷拉，你应该吗？
- ZIM 能否克服集装箱运输业的广泛衰退？
Receive News & Ratings for Pyxis Oncology Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pyxis Oncology and related companies with MarketBeat.com's FREE daily email newsletter.
接收 Pyxis Oncology Daily 的新闻和 -在下面输入您的电子邮件地址，通过Marketbeat.com的免费每日电子邮件时事通讯接收Pyxis Oncology及相关公司的最新新闻和分析师评级的简明每日摘要。
moomoo是Moomoo Technologies Inc.公司提供的金融信息和交易应用程序。
在美国，moomoo上的投资产品和服务由Moomoo Financial Inc.提供，一家受美国证券交易委员会（SEC）监管的持牌主体。 Moomoo Financial Inc.是金融业监管局（FINRA）和证券投资者保护公司（SIPC）的成员。
在新加坡，moomoo上的投资产品和服务是通过Moomoo Financial Singapore Pte. Ltd.提供，该公司受新加坡金融管理局（MAS）监管(牌照号码︰CMS101000) ，持有资本市场服务牌照 (CMS) ，持有财务顾问豁免（Exempt Financial Adviser）资质。本内容未经新加坡金融管理局的审查。
在澳大利亚，moomoo上的金融产品和服务是通过Futu Securities (Australia) Ltd提供，该公司是受澳大利亚证券和投资委员会(ASIC)监管的澳大利亚金融服务许可机构（AFSL No. 224663）。请阅读并理解我们的《金融服务指南》、《条款与条件》、《隐私政策》和其他披露文件，这些文件可在我们的网站 https://www.moomoo.com/au中获取。
在加拿大，通过moomoo应用提供的仅限订单执行的券商服务由Moomoo Financial Canada Inc.提供，并受加拿大投资监管机构（CIRO）监管。
在马来西亚，moomoo上的投资产品和服务是通过Moomoo Securities Malaysia Sdn. Bhd. 提供，该公司受马来西亚证券监督委员会（SC）监管(牌照号码︰eCMSL/A0397/2024) ，持有资本市场服务牌照 (CMSL) 。本内容未经马来西亚证券监督委员会的审查。
Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd., Futu Securities (Australia) Ltd, Moomoo Financial Canada Inc.,和Moomoo Securities Malaysia Sdn. Bhd.是关联公司。
风险及免责提示
moomoo是Moomoo Technologies Inc.公司提供的金融信息和交易应用程序。
在美国，moomoo上的投资产品和服务由Moomoo Financial Inc.提供，一家受美国证券交易委员会（SEC）监管的持牌主体。 Moomoo Financial Inc.是金融业监管局（FINRA）和证券投资者保护公司（SIPC）的成员。
在新加坡，moomoo上的投资产品和服务是通过Moomoo Financial Singapore Pte. Ltd.提供，该公司受新加坡金融管理局（MAS）监管(牌照号码︰CMS101000) ，持有资本市场服务牌照 (CMS) ，持有财务顾问豁免（Exempt Financial Adviser）资质。本内容未经新加坡金融管理局的审查。
在澳大利亚，moomoo上的金融产品和服务是通过Futu Securities (Australia) Ltd提供，该公司是受澳大利亚证券和投资委员会(ASIC)监管的澳大利亚金融服务许可机构（AFSL No. 224663）。请阅读并理解我们的《金融服务指南》、《条款与条件》、《隐私政策》和其他披露文件，这些文件可在我们的网站 https://www.moomoo.com/au中获取。
在加拿大，通过moomoo应用提供的仅限订单执行的券商服务由Moomoo Financial Canada Inc.提供，并受加拿大投资监管机构（CIRO）监管。
在马来西亚，moomoo上的投资产品和服务是通过Moomoo Securities Malaysia Sdn. Bhd. 提供，该公司受马来西亚证券监督委员会（SC）监管(牌照号码︰eCMSL/A0397/2024) ，持有资本市场服务牌照 (CMSL) 。本内容未经马来西亚证券监督委员会的审查。
Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd., Futu Securities (Australia) Ltd, Moomoo Financial Canada Inc.,和Moomoo Securities Malaysia Sdn. Bhd.是关联公司。
- 分享到weixin
- 分享到qq
- 分享到facebook
- 分享到twitter
- 分享到微博
- 粘贴板
使用浏览器的分享功能，分享给你的好友吧